CAS
RGLS

CTC Alternative Strategies’s Regulus Therapeutics RGLS Stock Holding History

CTC Alternative Strategies’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-18,500
Closed -$53.3K – 257
2024
Q1 		$53.3K Buy
+18,500
New +$30.2K 0.03% 112

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CTC Alternative Strategies's RGLS Position: Q2 2024 in Review

CTC Alternative Strategies sold out of Regulus Therapeutics (RGLS) in Q2 2024, closing a stake of 18,500 shares — an estimated $53.3K sold.

CTC Alternative Strategies first reported a position in RGLS in Q1 2024 and held it in 1 quarter. The position peaked at $53.3K in Q1 2024. 63 funds tracked by Wall St. Rank hold RGLS as of Q2 2024.

  • CTC Alternative Strategies reported no remaining Regulus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 18,500 Regulus Therapeutics shares in Q2 2024, an estimated $53.3K.
  • CTC Alternative Strategies first reported a position in Regulus Therapeutics in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's Regulus Therapeutics position peaked at $53.3K in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.